Concomitant resistance and early-breast cancer: Should we change treatment strategies?

Cancer and Metastasis Reviews

Volumn 33, Issue 1, 2014, Pages 271-283

  Galmarini, Carlos M ^a   Tredan, Olivier ^b   Galmarini, Felipe C ^a  

^a Fundación Marcel Dargent Escuela Sudamericana de Oncología Montevideo   (Argentina)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

Breast cancer; Concomitant resistance; Metastasis; Tumour dormancy

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CONCOMITANT RESISTANCE; DORMANCY; EARLY CANCER; GROWTH INHIBITION; HUMAN; IMMUNE SYSTEM; IMMUNITY; MARASMUS; MASTECTOMY; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RELAPSE; TREATMENT PLANNING; TUMOR CELL; TUMOR GROWTH; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; PATHOLOGY; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE;

ANTI-INFLAMMATORY AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNE SYSTEM; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84899907874     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9449-1     Document Type: Article

References (130)

1. Fisher, B., Anderson, S., Redmond, C. K., Wolmark, N., Wickerham, D. L., & Cronin, W. M. (1995). Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. The New England Journal of Medicine, 333(22), 1456-1461.
2. Veronesi, U., Saccozzi, R., Del Vecchio, M., Banfi, A., Clemente, C., De Lena, M., et al. (1981). Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. The New England Journal of Medicine, 305(1), 6-11.
3. Olson, J. A., Jr., McCall, L. M., Beitsch, P., Whitworth, P. W., Reintgen, D. S., Blumencranz, P. W., et al. (2008). Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. Journal of Clinical Oncology, 26(21), 3530-3535.
4. Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., et al. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 379(9814), 432-444.
5. Rachet, B., Maringe, C., Nur, U., Quaresma, M., Shah, A., Woods, L. M., et al. (2009). Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. The Lancet Oncology, 10(4), 351-369.
6. Bloom, H. J. G. (1964). The natural history of untreated breast cancer. Annals of the New York Academy of Sciences, 114, 747-754.
7. Demicheli, R., Retsky, M. W., Hrushesky, W. J., & Baum, M. (2007). Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nature Clinical Practice Oncology, 4(12), 699-710.
8. Karrison, T. G., Ferguson, D. J., & Meier, P. (1999). Dormancy of mammary carcinoma after mastectomy. Journal of the National Cancer Institute, 91(1), 80-85.
9. Jerez, J. M., Franco, L., Alba, E., Llombart-Cussac, A., Lluch, A., Ribelles, N., et al. (2005). Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. Breast Cancer Research and Treatment, 94(3), 265-272.
10. Sant, M., Gatta, G., Micheli, A., Verdecchia, A., Capocaccia, R., Crosignani, P., et al. (1991). Survival and age at diagnosis of breast cancer in a population-based cancer registry. European Journal of Cancer, 27(8), 981-984.
11. Baum, M., & Badwe, R. A. (1994). Does surgery influence the natural history of breast cancer? In H. Wise & H. J. Johnson (Eds.), Breast cancer: Controversies in management (pp. 61-69). Armonk, NY: Futura.
12. Yakovlev, A. Y., Tsodikov, A. D., Boucher, K., & Kerber, R. (1999). The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer, 85(8), 1789-1798.
13. Gao, F., Tan, S. B., Machin, D., & Wong, N. S. (2007). Confirmation of double-peaked time distribution of mortality among Asian breast cancer patients in a population-based study. Breast Cancer Research, 9(2), R21.
14. Retsky, M., Demicheli, R., & Hrushesky, W. (2001). Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Research and Treatment, 65(3), 217-224.
15. Crowe, J. P., Jr., Gordon, N. H., Antunez, A. R., Shenk, R. R., Hubay, C. A., & Shuck, J. M. (1991). Local-regional breast cancer recurrence following mastectomy. Archives of Surgery, 126(4), 429-432.
16. Fortin, A., Larochelle, M., Laverdiere, J., Lavertu, S., & Tremblay, D. (1999). Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. Journal of Clinical Oncology, 17(1), 101-109.
17. Saphner, T., Tormey, D. C., & Gray, R. (1996). Annual hazard rates of recurrence for breast cancer after primary therapy. Journal of Clinical Oncology, 14(10), 2738-2746.
18. Jatoi, I., Tsimelzon, A., Weiss, H., Clark, G. M., & Hilsenbeck, S. G. (2005). Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Research and Treatment, 89(2), 173-178.
19. Gasparini, G., Biganzoli, E., Bonoldi, E., Morabito, A., Fanelli, M., & Boracchi, P. (2001). Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. Breast Cancer Research and Treatment, 65(1), 71-75.
20. Ripley, R. M., Harris, A. L., & Tarassenko, L. (2004). Non-linear survival analysis using neural networks. Statistics in Medicine, 23(5), 825-842.
21. Demicheli, R., Valagussa, P., & Bonadonna, G. (2002). Double-peaked time distribution of mortality for breast cancer patients undergoing mastectomy. Breast Cancer Research and Treatment, 75(2), 127-134.
22. Demicheli, R., Miceli, R., Brambilla, C., Ferrari, L., Moliterni, A., Zambetti, M., et al. (1999). Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'. Breast Cancer Research and Treatment, 53(3), 209-215.
23. Demicheli, R., Miceli, R., Moliterni, A., Zambetti, M., Hrushesky, W. J., Retsky, M. W., et al. (2005). Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Annals of Oncology, 16(9), 1449-1457.
24. Norton, L., & Simon, R. (1977). Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treatment Reports, 61(7), 1307-1317.
25. Wiedswang, G., Borgen, E., Karesen, R., Kvalheim, G., Nesland, J. M., Qvist, H., et al. (2003). Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. Journal of Clinical Oncology, 21(18), 3469-3478.
26. Wiedswang, G., Borgen, E., Karesen, R., Qvist, H., Janbu, J., Kvalheim, G., et al. (2004). Isolated tumor cells in bone marrow 3 years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clinical Cancer Research, 10(16), 5342-5348.
27. Diel, I. J., Kaufmann, M., Costa, S. D., Holle, R., von Minckwitz, G., Solomayer, E. F., et al. (1996). Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. Journal of the National Cancer Institute, 88(22), 1652-1658.
28. Gebauer, G., Fehm, T., Merkle, E., Beck, E. P., Lang, N., & Jager, W. (2001). Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. Journal of Clinical Oncology, 19(16), 3669-3674.
29. Cote, R. J., Rosen, P. P., Lesser, M. L., Old, L. J., & Osborne, M. P. (1991). Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. Journal of Clinical Oncology, 9(10), 1749-1756.
30. Mansi, J. L., Easton, D., Berger, U., Gazet, J. C., Ford, H. T., Dearnaley, D., et al. (1991). Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. European Journal of Cancer, 27(12), 1552-1555.
31. Becker, S., Becker-Pergola, G., Wallwiener, D., Solomayer, E. F., & Fehm, T. (2006). Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Research and Treatment, 97(1), 91-96.
32. Braun, S., Kentenich, C., Janni, W., Hepp, F., de Waal, J., Willgeroth, F., et al. (2000). Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. Journal of Clinical Oncology, 18(1), 80-86.
33. Janni, W., Rack, B., Schindlbeck, C., Strobl, B., Rjosk, D., Braun, S., et al. (2005). The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer, 103(5), 884-891.
34. Meng, S., Tripathy, D., Frenkel, E. P., Shete, S., Naftalis, E. Z., Huth, J. F., et al. (2004). Circulating tumor cells in patients with breast cancer dormancy. Clinical Cancer Research, 10(24), 8152-8162.
35. Bidard, F. C., Fehm, T., Ignatiadis, M., Smerage, J. B., Alix-Panabieres, C., Janni, W., et al. (2013). Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer and Metastasis Reviews, 32(1-2), 179-188.
36. Ruggiero, R. A., Bruzzo, J., Chiarella, P., Bustuoabad, O. D., Meiss, R. P., & Pasqualini, C. D. (2012). Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control. Cancer Research, 72(5), 1043-1050.
37. Franco, M., Bustuoabad, O. D., di Gianni, P. D., Goldman, A., Pasqualini, C. D., & Ruggiero, R. A. (1996). A serum-mediated mechanism for concomitant resistance shared by immunogenic and non-immunogenic murine tumours. British Journal of Cancer, 74(2), 178-186.
38. North, R. J. (1984). The murine antitumor immune response and its therapeutic manipulation. Advances in Immunology, 35, 89-155.
39. Quesnel, B. (2008). Tumor dormancy and immunoescape. APMIS, 116(7-8), 685-694.
40. Nagaraj, S., & Gabrilovich, D. I. (2008). Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Research, 68(8), 2561-2563.
41. Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007). Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology, 25, 267-296.
42. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., et al. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79(2), 315-328.
43. Ruggiero, R. A., Bustuoabad, O. D., Cramer, P., Bonfil, R. D., & Pasqualini, C. D. (1990). Correlation between seric antitumor activity and concomitant resistance in mice bearing nonimmunogenic tumors. Cancer Research, 50(22), 7159-7165.
44. Ruggiero, R. A., Bruzzo, J., Chiarella, P., di Gianni, P., Isturiz, M. A., Linskens, S., et al. (2011). Tyrosine isomers mediate the classical phenomenon of concomitant tumor resistance. Cancer Research, 71(22), 7113-7124.
45. Gorelik, E. (1983). Concomitant tumor immunity and the resistance to a second tumor challenge. Advances in Cancer Research, 39, 71-120.
46. Kusmartsev, S., & Gabrilovich, D. I. (2006). Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunology, Immunotherapy, 55(3), 237-245.
47. Yu, P., Rowley, D. A., Fu, Y. X., & Schreiber, H. (2006). The role of stroma in immune recognition and destruction of well-established solid tumors. Current Opinion in Immunology, 18(2), 226-231.
48. Baker, D. G., Masterson, T. M., Pace, R., Constable, W. C., & Wanebo, H. (1989). The influence of the surgical wound on local tumor recurrence. Surgery, 106(3), 525-532.
49. Hofer, S. O., Shrayer, D., Reichner, J. S., Hoekstra, H. J., & Wanebo, H. J. (1998). Wound-induced tumor progression: a probable role in recurrence after tumor resection. Archives of Surgery, 133(4), 383-389.
50. Decker, D., Schondorf, M., Bidlingmaier, F., Hirner, A., & von Ruecker, A. A. (1996). Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma. Surgery, 119(3), 316-325.
51. Hansbrough, J. F., Bender, E. M., Zapata-Sirvent, R., & Anderson, J. (1984). Altered helper and suppressor lymphocyte populations in surgical patients. A measure of postoperative immunosuppression. American Journal of Surgery, 148(3), 303-307.
52. Hormbrey, E., Han, C., Roberts, A., McGrouther, D. A., & Harris, A. L. (2003). The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. Clinical Cancer Research, 9(12), 4332-4339.
53. Tagliabue, E., Agresti, R., Carcangiu, M. L., Ghirelli, C., Morelli, D., Campiglio, M., et al. (2003). Role of HER2 in wound-induced breast carcinoma proliferation. Lancet, 362(9383), 527-533.
54. Wu, F. P., Hoekman, K., Meijer, S., & Cuesta, M. A. (2003). VEGF and endostatin levels in wound fluid and plasma after breast surgery. Angiogenesis, 6(4), 255-257.
55. Ali, S., & Lazennec, G. (2007). Chemokines: novel targets for breast cancer metastasis. Cancer and Metastasis Reviews, 26(3-4), 401-420.
56. Snyder, G. L., & Greenberg, S. (2010). Effect of anaesthetic technique and other perioperative factors on cancer recurrence. British Journal of Anaesthesia, 105(2), 106-115.
57. Coffey, J. C., Wang, J. H., Smith, M. J., Bouchier-Hayes, D., Cotter, T. G., & Redmond, H. P. (2003). Excisional surgery for cancer cure: therapy at a cost. The Lancet Oncology, 4(12), 760-768.
58. Hrushesky, W. J. (2000). Rhythmic menstrual cycle modulation of breast cancer biology. Journal of Surgical Oncology, 74(3), 238-241.
59. Veronesi, U., Luini, A., Mariani, L., Del Vecchio, M., Alvez, D., Andreoli, C., et al. (1994). Effect of menstrual phase on surgical treatment of breast cancer. Lancet, 343(8912), 1545-1547.
60. Jones, B., & Russo, J. (1987). Influence of steroid hormones on the growth fraction of human breast carcinomas. American Journal of Clinical Pathology, 88(2), 132-138.
61. Heer, K., Kumar, H., Speirs, V., Greenman, J., Drew, P. J., Fox, J. N., et al. (1998). Vascular endothelial growth factor in premenopausal women-indicator of the best time for breast cancer surgery? British Journal of Cancer, 78(9), 1203-1207.
62. Hrushesky, W. J., Gruber, S. A., Sothern, R. B., Hoffman, R. A., Lakatua, D., Carlson, A., et al. (1988). Natural killer cell activity: age, estrous- and circadian-stage dependence and inverse correlation with metastatic potential. Journal of the National Cancer Institute, 80(15), 1232-1237.
63. Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295(21), 2492-2502.
64. Chlebowski, R. T., Chen, Z., Anderson, G. L., Rohan, T., Aragaki, A., Lane, D., et al. (2005). Ethnicity and breast cancer: factors influencing differences in incidence and outcome. Journal of the National Cancer Institute, 97(6), 439-448.
65. McDaniel, S. M., Rumer, K. K., Biroc, S. L., Metz, R. P., Singh, M., Porter, W., et al. (2006). Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. The American Journal of Pathology, 168(2), 608-620.
66. Schedin, P. (2006). Pregnancy-associated breast cancer and metastasis. Nature Reviews Cancer, 6(4), 281-291.
67. Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., et al. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research, 13(15 Pt 1), 4429-4434.
68. Carey, L. A. (2011). Directed therapy of subtypes of triple-negative breast cancer. The Oncologist, 16(Suppl 1), 71-78.
69. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer, 109(9), 1721-1728.
70. Lianidou, E. S., Markou, A., & Strati, A. (2012). Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment. Cancer and Metastasis Reviews, 31(3-4), 663-671.
71. Fehm, T., Hoffmann, O., Aktas, B., Becker, S., Solomayer, E. F., Wallwiener, D., et al. (2009). Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Research, 11(4), R59.
72. Aktas, B., Muller, V., Tewes, M., Zeitz, J., Kasimir-Bauer, S., Loehberg, C. R., et al. (2011). Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecologic Oncology, 122(2), 356-360.
73. Kushi, L. H., Byers, T., Doyle, C., Bandera, E. V., McCullough, M., McTiernan, A., et al. (2006). American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA: A Cancer Journal for Clinicians, 56(5), 254-281. quiz 313-254.
74. Ursin, G., Bernstein, L., Wang, Y., Lord, S. J., Deapen, D., Liff, J. M., et al. (2004). Reproductive factors and risk of breast carcinoma in a study of white and African-American women. Cancer, 101(2), 353-362.
75. Breasted, J. H. (1930). The Edwin Smith Surgical Papyrus. Chicago: The University of Chicago Press.
76. Chakrabarti, J., Kenny, F. S., Syed, B. M., Robertson, J. F., Blamey, R. W., & Cheung, K. L. (2011). A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up. Critical Reviews in Oncology/Hematology, 78(3), 260-264.
77. Hirai, T., Matsumoto, H., Kubota, H., & Yamaguchi, Y. (2013). Regulating surgical oncotaxis to improve the outcomes in cancer patients. Surg Today, in press
78. Bonadonna, G., Zambetti, M., & Valagussa, P. (1989). Adjuvant chemotherapy for node-negative breast cancer patients. Recent Results in Cancer Research, 115, 175-179.
79. Castiglione-Gertsch, M., Tattersall, M., Hacking, A., Goldhirsch, A., Gudgeon, A., Gelber, R. D., et al. (1997). Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. European Journal of Cancer, 33(14), 2321-2325.
80. Valagussa, P., Brambilla, C., Zambetti, M., & Bonadonna, G. (1989). Salvage treatments in relapsing resectable breast cancer. Recent Results in Cancer Research, 115, 69-76.
81. Galmarini, D., Galmarini, C. M., & Galmarini, F. C. (2012). Cancer chemotherapy: A critical analysis of its 60 years of history. Critical Reviews in Oncology/Hematology, 84(2), 181-199.
82. Pasquier, E., Kavallaris, M., & Andre, N. (2010). Metronomic chemotherapy: New rationale for new directions. Nature Reviews. Clinical Oncology, 7(8), 455-465.
83. Kerbel, R. S. (2011). Reappraising antiangiogenic therapy for breast cancer. Breast, 20(Suppl 3), S56-60.
84. Luster, A. D. (1998). Chemokines-chemotactic cytokines that mediate inflammation. The New England Journal of Medicine, 338(7), 436-445.
85. Retsky, M. W., Hrushesky, W. J., & Gukas, I. D. (2009). Hypothesis: Primary antiangiogenic method proposed to treat early stage breast cancer. BMC Cancer, 9, 7.
86. Murphy, P. M., Baggiolini, M., Charo, I. F., Hebert, C. A., Horuk, R., Matsushima, K., et al. (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacological Reviews, 52(1), 145-176.
87. Singh, J. K., Farnie, G., Bundred, N. J., Simoes, B. M., Shergill, A., Landberg, G., et al. (2013). Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clinical Cancer Research, 19(3), 643-656.
88. Kiderlen, M., de Glas, N. A., Bastiaannet, E., Engels, C. C., van de Water, W., de Craen, A. J., et al. (2013). Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: a FOCUS study analysis. Annals of Oncology, 24, 3011-3016
89. Niraula, S., Dowling, R. J., Ennis, M., Chang, M. C., Done, S. J., Hood, N., et al. (2012). Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Research and Treatment, 135(3), 821-830.
90. Siclari, V. A., Guise, T. A., & Chirgwin, J. M. (2006). Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer and Metastasis Reviews, 25(4), 621-633.
91. Winter, M. C., & Coleman, R. E. (2013). Bisphosphonates in the adjuvant treatment of breast cancer. Clinical Oncology (Royal College of Radiologists), 25(2), 135-145.
92. Fehm, T., Zwirner, M., Wallwiener, D., Seeger, H., & Neubauer, H. (2012). Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer, 12, 308.
93. Misso, G., Porru, M., Stoppacciaro, A., Castellano, M., De Cicco, F., Leonetti, C., et al. (2012). Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biology and Therapy, 13(14), 1491-1500.
94. Giovannini, M., Aldrighetti, D., Zucchinelli, P., Belli, C., & Villa, E. (2010). Antiangiogenic strategies in breast cancer management. Critical Reviews in Oncology/Hematology, 76(1), 13-35.
95. Amadori, D., Aglietta, M., Alessi, B., Gianni, L., Ibrahim, T., Farina, G., et al. (2013). Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): A phase 3, open-label, randomised, non-inferiority trial. The Lancet Oncology, 14(7), 663-670.
96. Dedes, P. G., Kanakis, I., Gialeli, C., Theocharis, A. D., Tsegenidis, T., Kletsas, D., et al. (2013). Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease. Biochimica et Biophysica Acta, 1830(6), 3625-3634.
97. Paterson, A. H., Anderson, S. J., Lembersky, B. C., Fehrenbacher, L., Falkson, C. I., King, K. M., et al. (2012). Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial. The Lancet Oncology, 13(7), 734-742.
98. Gottschalk, A., Sharma, S., Ford, J., Durieux, M. E., & Tiouririne, M. (2010). Review article: The role of the perioperative period in recurrence after cancer surgery. Anesthesia and Analgesia, 110(6), 1636-1643.
99. Forget, P., Vandenhende, J., Berliere, M., Machiels, J. P., Nussbaum, B., Legrand, C., et al. (2010). Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesthesia and Analgesia, 110(6), 1630-1635.
100. Retsky, M., Rogers, R., Demicheli, R., Hrushesky, W. J., Gukas, I., Vaidya, J. S., et al. (2012). NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: Particular relevance to triple negative subgroup. Breast Cancer Research and Treatment, 134(2), 881-888.
101. Howe, L. R. (2007). Inflammation and breast cancer. Cyclooxygenase/ prostaglandin signaling and breast cancer. Breast Cancer Res, 9(4), 210.
102. Singh, B., Berry, J. A., Vincent, L. E., & Lucci, A. (2006). Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. The Journal of Surgical Research, 134(1), 44-51.
103. Singh, B., & Lucci, A. (2002). Role of cyclooxygenase-2 in breast cancer. The Journal of Surgical Research, 108(1), 173-179.
104. Bendre, M. S., Montague, D. C., Peery, T., Akel, N. S., Gaddy, D., & Suva, L. J. (2003). Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone, 33(1), 28-37.
105. Falandry, C., Canney, P. A., Freyer, G., & Dirix, L. Y. (2009). Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Annals of Oncology, 20(4), 615-620.
106. Lustberg, M. B., Povoski, S. P., Zhao, W., Ziegler, R. M., Sugimoto, Y., Ruppert, A. S., et al. (2011). Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clinical Breast Cancer, 11(4), 221-227.
107. Perroud, H. A., Rico, M. J., Alasino, C. M., Queralt, F., Mainetti, L. E., Pezzotto, S. M., et al. (2013). Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncology, 9(3), 451-462.
108. Roh, J. L., Sung, M. W., & Kim, K. H. (2005). Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin. Head and Neck, 27(4), 326-332.
109. Zhou, D., Papayannis, I., Mackenzie, G. G., Alston, N., Ouyang, N., Huang, L., et al. (2013). The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. Carcinogenesis, 34(4), 943-951.
110. DiDonato, J. A., Mercurio, F., & Karin, M. (2012). NF-kappaB and the link between inflammation and cancer. Immunology Reviews, 246(1), 379-400.
111. Wu, J. T., & Kral, J. G. (2005). The NF-kappaB/IkappaB signaling system: A molecular target in breast cancer therapy. The Journal of Surgical Research, 123(1), 158-169.
112. Watanabe, M. A., Oda, J. M., Amarante, M. K., & Cesar Voltarelli, J. (2010). Regulatory T cells and breast cancer: Implications for immunopathogenesis. Cancer and Metastasis Reviews, 29(4), 569-579.
113. DeNardo, D. G., & Coussens, L. M. (2007). Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res, 9(4), 212.
114. Wang, H. Y., & Wang, R. F. (2007). Regulatory T cells and cancer. Current Opinion in Immunology, 19(2), 217-223.
115. Thornton, A. M., & Shevach, E. M. (1998). CD4∈+∈CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. The Journal of Experimental Medicine, 188(2), 287-296.
116. Tarabichi, M., Antoniou, A., Saiselet, M., Pita, J. M., Andry, G., Dumont, J. E., et al. (2013). Systems biology of cancer: Entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence". Cancer Metastasis Reviews, 32, 403-421.
117. Whiteside, T. L. (2006). Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Seminars in Cancer Biology, 16(1), 3-15.
118. Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., et al. (2006). Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of Clinical Oncology, 24(34), 5373-5380.
119. Ghebeh, H., Barhoush, E., Tulbah, A., Elkum, N., Al-Tweigeri, T., & Dermime, S. (2008). FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer, 8, 57.
120. Ohara, M., Yamaguchi, Y., Matsuura, K., Murakami, S., Arihiro, K., & Okada, M. (2009). Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunology, Immunotherapy, 58(3), 441-447.
121. Zhou, X., Bailey-Bucktrout, S., Jeker, L. T., & Bluestone, J. A. (2009). Plasticity of CD4(+) FoxP3(+) T cells. Current Opinion in Immunology, 21(3), 281-285.
122. Alam, S. M., Clark, J. S., George, W. D., & Campbell, A. M. (1993). Altered lymphocyte populations in tumour invaded nodes of breast cancer patients. Immunology Letters, 35(3), 229-234.
123. Nakamura, R., Sakakibara, M., Nagashima, T., Sangai, T., Arai, M., Fujimori, T., et al. (2009). Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. European Journal of Cancer, 45(12), 2123-2131.
124. Matsuura, K., Yamaguchi, Y., Osaki, A., Ohara, M., Okita, R., Emi, A., et al. (2009). FOXP3 expression of micrometastasis-positive sentinel nodes in breast cancer patients. Oncology Reports, 22(5), 1181-1187.
125. Hasan, A., Ghebeh, H., Lehe, C., Ahmad, R., & Dermime, S. (2011). Therapeutic targeting of B7-H1 in breast cancer. Expert Opinion on Therapeutic Targets, 15(10), 1211-1225.
126. Emens, L. A. (2012). Breast cancer immunobiology driving immunotherapy: Vaccines and immune checkpoint blockade. Expert Review of Anticancer Therapy, 12(12), 1597-1611.
127. Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013). Immunogenic cell death in cancer therapy. Annual Review of Immunology, 31, 51-72.
128. Denkert, C., Darb-Esfahani, S., Loibl, S., Anagnostopoulos, I., & Johrens, K. (2011). Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Seminars in Immunopathology, 33(4), 341-351.
129. Beano, A., Signorino, E., Evangelista, A., Brusa, D., Mistrangelo, M., Polimeni, M. A., et al. (2008). Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. Journal of Translational Medicine, 6, 25.
130. Demicheli, R., Valagussa, P., & Bonadonna, G. (2001). Does surgery modify growth kinetics of breast cancer micrometastases? British Journal of Cancer, 85(4), 490-492.